Mirac inhibits the heightened stimulation of the HPA axis, (Hypothalmic-Pituitary-Adrenal) in the Neuro-Endocrine loop, responding in the over awareness of pain. (Scand J Rheumatol Suppl. 2000;113:8-12. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Neeck G. Department of Rheumatology, Kerckhoff Clinic and Foundation, Bad Nauheim, Germany.)

Mirac shuts down the neuroinflammation that causes Fibromyalgia by normalizing the hyper-polarization of the Adrenal Cortex and suppression of glucagon. Kv1.7+, the insulin releasing channel is potentiated and glucose transport is re-abled. The hormones attenuate and the patient “feels good” again as the global insult ceases and normal metabolic transport re-establishes.

Fibromyalgia (fi-bro-my-AL-ja) syndrome (FMS) produces chronic body-wide pain, which migrates and can be felt from head to toe. Other symptoms include persistent fatigue, headaches, cognitive or memory impairment, morning stiffness and non-restorative sleep. The pain can migrate from day to day. Recent scientific research studies have shown central nervous system involvement in FMS.

The symptomatology of the fibromyalgia syndrome (FMS) often resembles an alteration in central nervous set points at least in three systems. The patients suffer under chronic pain in the region of the locomotor system, presumably reflecting a disturbed central processing of pain. Anxiety and depression often characterizes the clinical picture. Almost all of the hormonal feedback mechanisms controlled by the hypothalamus are altered. Characteristic for FMS patients are the elevated basal values of ACTH, follicle-stimulating hormone (FSH), and cortisol as well as lowered basal values of insulin-like growth factor 1 (IGF-1, somatomedin C), free triiodothyronine (FT3), and oestrogen. In FMS patients, the systemic administration of the relevant releasing hormones of corticotropin-releasing hormone (CRH), growth hormone-releasing hormone (GHRH), thyreotropin-releasing hormone (TRH), and luteinizing hormone-releasing hormone (LHRH) leads to increased secretion of ACTH and prolactin, whereas the degree to which TSH can be stimulated is reduced. The stimulation of the hypophysis with LHRH in female FMS patients during their follicular phase results in a significantly reduced LH response. All in all, the typical alterations in set points of hormonal regulation that are typical for FMS patients can be explained as a primary stress activation of hypothalamic CRH neurons caused by the chronic pain. In addition to the stimulation of pituitary ACTH secretion, CRH activates somatostatin on the hypothalamic level, which in turn inhibits the release of GH and TSH on the hypophyseal level. The lowered oestrogen levels could be accounted for both via an inhibitory effect of the CRH on the hypothalamic release of LHRH or via a direct CRH-mediated inhibition of the FSH-stimulated oestrogen production in the ovary. Serotonin (5HT), precursors like tryptophan (5HTP), drugs which release 5HT or act directly on 5HT receptors stimulate HPA axis, indicating a stimulatory serotonergic influence on HPA axis function. Therefore activation of the HPA axis may reflect an elevated serotonergic tonus in the central nervous system of FMS patients.

Mirac is designed to pre-empt and reverse this devastating neuronal misconstruct by balancing 64 differing cellular mechanisms to regain a normal and healthy state. The Effects of Plant Flavonoids on Mammalian Cells: Implications for Heart Disease, Inflammation and Heart Disease, vol.52, No 4, 47/86401 E. Middleton. Jr.et.al., Pharmacological Reviews http//www.pharmrev.org

Mirac stops the proliferation of trigger points that cause the pain of Fibromyalgia. Over 6 million Americans, 90% of them women in the prime of their life, suffer from FMS and sometimes struggle for years before being correctly diagnosed. Symptoms usually appear between 20-55 years of age, but children are also diagnosed with fibromyalgia syndrome. Pain and severe fatigue may keep FMS sufferers from their chosen profession and unable to perform common daily tasks.

Fibromyalgia Syndrome Diagnostic Criteria

Fibromyalgia is a distinctive syndrome which can be diagnosed with clinical precision. It may occur in the absence (primary fibromyalgia) or presence of other conditions such as rheumatoid arthritis or systemic lupus erythematosus (concomitant fibromyalgia). It is rarely secondary to another disease, in the sense that alleviation of the associated disease also cures the fibromyalgia. It may be confidently diagnosed in patients with widespread musculo-skeletal pain and multiple tender points.

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia

History of widespread pain has been present for at least three months. Definition: Pain is considered widespread when all of the following are present: Pain in both sides of the body Pain above and below the waist. In addition, axial skeletal pain (cervical spine, anterior chest, thoracic spine or low back pain) must be present. Low back pain is considered lower segment pain.

Pain in 11 of 18 tender point sites on digital palpation Definition: Pain, on digital palpation, must be present in at least 11 of the following 18 tender point sites: Occiput (2) - at the suboccipital muscle insertions.

Low cervical (2) - at the anterior aspects of the intertransverse spaces at C5-C7. Trapezius (2) - at the midpoint of the upper border.

Supraspinatus (2) - at origins, above the scapula spine near the medial border. Second rib (2) - upper lateral to the second costochondral junction.

Lateral epicondyle (2) - 2 cm distal to the epicondyles. Gluteal (2) - in upper outer quadrants of buttocks in anterior fold of muscle. Greater trochanter (2) - posterior to the trochanteric prominence. Knee (2) - at the medial fat pad proximal to the joint line. Digital palpation should be performed with an approximate force of 4 kg. A tender point has to be painful at palpation, not just "tender."

Illustration of Tender Points

Fibromyalgia Syndrome Symptoms Arthritis and Rheumatism, Vol. 33, No. 2, Feb 1990, F. Wolfe, et al.

Toxicology. 2000 Nov 30;155(1-3):45-53. Antioxidants in vegan diet and rheumatic disorders. Hanninen, Kaartinen K, Rauma AL, Nenonen M, Torronen R, Hakkinen AS, Adlercreutz H, Laakso J. Department of Physiology, University of Kuopio, Finland. Plants are rich natural sources of antioxidants in addition to other nutrients. Interventions and cross sectional studies on subjects consuming uncooked vegan diet called living food (LF) have been carried out. We have clarified the efficacy of LF in rheumatoid diseases as an example of a health problem where inflammation is one of the main concerns. LF is an uncooked vegan diet and consists of berries, fruits, vegetables and roots, nuts, germinated seeds and sprouts, i.e. rich sources of carotenoids, vitamins C and E. The subjects eating LF showed highly increased levels of beta and alfa carotenes, lycopen and lutein in their sera. Also the increases of vitamin C and vitamin E (adjusted to cholesterol) were statistically significant. As the berry intake was 3-fold compared to controls the intake of polyphenolic compounds like quercetin, myricetin and kaempherol was much higher than in the omnivorous controls. The LF diet is rich in fibre, substrate of lignan production, and the urinary excretion of polyphenols like enterodiol and enterolactone as well as secoisolaricirecinol were much increased in subjects eating LF. The shift of fibromyalgic subjects to LF resulted in a decrease of their joint stiffness and pain as well as an improvement of their self-experienced health. The rheumatoid arthritis patients eating the LF diet also reported similar positive responses and the objective measures supported this finding. The improvement of rheumatoid arthritis was significantly correlated with the day-to-day fluctuation of subjective symptoms. In conclusion the rheumatoid patients subjectively benefited from the vegan diet rich in antioxidants, lactobacilli and fibre, and this was also seen in objective measures.

Publication Types: Clinical Trial Randomized Controlled Trial PMID: 11156742 [PubMed - indexed for MEDLINE]

Back to top